StockDuty ← Dashboard Oct 18, 2026 02:43 AM ET
SignalFDA/Bio

PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow

PDS-0301 immunocytokine discussed for metastatic colorectal cancer treatment.

What happened: PDS Biotechnology Corporation ($PDSB) published a slide deck in conjunction with an event discussing PDS-0301 immunocytokine and its role in treating metastatic colorectal cancer. Why it matters: The content provides no stated analyst reaction, market move, or guidance change, so no significance is expressed beyond the presentation itself. Total characters: about 330.
PDS Biotechnology Corporation ($PDSB) published a slide deck in conjunction with an event discussing PDS-0301 immunocytokine and its role in treating metastatic colorectal cancer.
The content provides no stated analyst reaction, market move, or guidance change, so no significance is expressed beyond the presentation itself. Total characters: about 330.
Sources